These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23081815)

  • 1. Assessment of antigen-specific and cross-reactive antibody responses to an MF59-adjuvanted A/H5N1 prepandemic influenza vaccine in adult and elderly subjects.
    Bihari I; Pánczél G; Kovacs J; Beygo J; Fragapane E
    Clin Vaccine Immunol; 2012 Dec; 19(12):1943-8. PubMed ID: 23081815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of an investigational tetravalent influenza vaccine formulation combining MF59®: adjuvanted, pre-pandemic, A/H5N1 vaccine and trivalent seasonal influenza vaccine in healthy adults.
    Herbinger KH; von Sonnenburg F; Nothdurft HD; Perona P; Borkowski A; Fragapane E; Nicolay U; Clemens R
    Hum Vaccin Immunother; 2014; 10(1):92-9. PubMed ID: 24047817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
    Vesikari T; Forstén A; Borkowski A; Gaitatzis N; Banzhoff A; Clemens R
    Hum Vaccin Immunother; 2012 Jul; 8(7):921-8. PubMed ID: 22777094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A heterologous MF59-adjuvanted H5N1 prepandemic influenza booster vaccine induces a robust, cross-reactive immune response in adults and the elderly.
    Fragapane E; Gasparini R; Schioppa F; Laghi-Pasini F; Montomoli E; Banzhoff A
    Clin Vaccine Immunol; 2010 Nov; 17(11):1817-9. PubMed ID: 20810680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults.
    Banzhoff A; Gasparini R; Laghi-Pasini F; Staniscia T; Durando P; Montomoli E; Capecchi PL; di Giovanni P; Sticchi L; Gentile C; Hilbert A; Brauer V; Tilman S; Podda A
    PLoS One; 2009; 4(2):e4384. PubMed ID: 19197383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II, randomised clinical trial to demonstrate the non-inferiority of low-dose MF59-adjuvanted pre-pandemic A/H5N1 influenza vaccine in adult and elderly subjects.
    Czajka H; Unal S; Ulusoy S; Usluer G; Strus A; Sennaroglu E; Guzik J; Topeli Iskit A; Dargiewicz A; Musial D; Caylan R; Dziduch J; Eskioglu E; Hasiec B; Cwinarowiczliwa E; Belli R; Abdel-Messih IA; Beygo J; Fragapane E
    J Prev Med Hyg; 2012 Sep; 53(3):136-42. PubMed ID: 23362618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly.
    Vesikari T; Forstén A; Herbinger KH; Cioppa GD; Beygo J; Borkowski A; Groth N; Bennati M; von Sonnenburg F
    Vaccine; 2012 Feb; 30(7):1388-96. PubMed ID: 22192847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.
    Izurieta P; Uy-Aragon MJ; Dramé M; Vaughn DW
    Pediatr Infect Dis J; 2016 Feb; 35(2):e35-47. PubMed ID: 26551446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability and Immunogenicity of an MF59-adjuvanted, Cell Culture-derived, A/H5N1, Subunit Influenza Virus Vaccine: Results From a Dose-finding Clinical Trial in Healthy Pediatric Subjects.
    Chanthavanich P; Anderson E; Kerdpanich P; Bulitta M; Kanesa-Thasan N; Hohenboken M
    Pediatr Infect Dis J; 2019 Jul; 38(7):757-764. PubMed ID: 31194712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.
    Gillard P; Chu DW; Hwang SJ; Yang PC; Thongcharoen P; Lim FS; Dramé M; Walravens K; Roman F
    BMC Infect Dis; 2014 Mar; 14():142. PubMed ID: 24628789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity profiles of an adjuvanted seasonal influenza vaccine in Guatemalan children.
    Solares AR; Aragon CG; Pivaral RU; Prado-Cohrs D; Sales-Carmona V; Pellegrini M; Groth N
    J Infect Dev Ctries; 2014 Sep; 8(9):1160-8. PubMed ID: 25212080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
    Langley JM; Frenette L; Jeanfreau R; Halperin SA; Kyle M; Chu L; McNeil S; Dramé M; Moris P; Fries L; Vaughn DW
    Vaccine; 2015 Jan; 33(4):559-67. PubMed ID: 25448092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Clemens R; Banzhoff A
    Clin Vaccine Immunol; 2013 May; 20(5):753-8. PubMed ID: 23536690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.
    Nagai H; Ikematsu H; Tenjinbaru K; Maeda A; Dramé M; Roman FP
    BMC Infect Dis; 2010 Nov; 10():338. PubMed ID: 21108818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.